Effect of Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth
Prenatal Depression, Ketamine, Postpartum Depression
About this trial
This is an interventional prevention trial for Prenatal Depression focused on measuring Prenatal Depression, Esketamine, Postpartum Depression, Long-Term Prognosis
Eligibility Criteria
All 364 pregnant women who participated in the underling trial "Effect of low-dose esketamine on the incidence of postpartum depression in women with prenatal depression: a randomized, double-blind, placebo-controlled trial" NCT04414943)and agreed to accept this 2-year follow-up. The inclusion criteria of the underlying trial: Maternal age ≥18 years; Prenatal Edinburgh postnatal depression scale score ≥10 points. Exclusion Criteria of the previous study: A clear history of mental illness (depression, schizophrenia, etc.) or communication disorders Severe pregnancy complications (such as severe preeclampsia, placenta accreta, HELLP syndrome, placenta previa, placenta abruption) before surgery; ASA grade ≥III; The presence of contraindications to ketamine/esketamine use (e.g., stubborn, refractory hypertension, severe cardiovascular disease [cardiac function grade ≥III], hyperthyroidism).
Sites / Locations
- Hunan Provincial Maternal and Child Health Care Hospital
- Women's Hospital of Nanjing Medical University
- Women's Hospital, Zhejiang University School of Medicine
- Peking University First Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Esketamine group
placebo group
For women in this group, study drug (esketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.